Publisher
Springer Science and Business Media LLC
Reference90 articles.
1. Kelly WN, Arellano FM, Barnes J, et al. For International Society of Pharmacoepidemiology and International Society of Pharmacovigilance. Guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30:367–73.
2. Haramburu F, Bégaud B, Péré JC. Comparison of 500 spontaneous and 500 published reports of adverse drug reactions. Eur J Clin Pharmacol. 1990;39:287–8.
3. Plessis L, Gómez A, García N, Cereza G, Figueras A. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection. Eur J Clin Pharmacol. 2017;73:751–8.
4. Ohashi Y, Suzuki K, Sakurai M, et al. Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury [in Japanese]. Gan To Kagaku Ryoho. 2010;37:1307–11.
5. Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Jpn J Clin Oncol. 2012;42:528–33.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献